Business Context and Reporting Period
Company: Mustang Bio, Inc. (MBIO)
Filing Type: Form 8-K (Current Report)
Date of Report: December 28, 2023
Event: Update on the sale of the Company's leasehold interest and associated assets of its cell processing facility in Worcester, Massachusetts, to uBrigene (Boston) Biosciences, Inc. (uBrigene).
Key Financial Metrics
This filing is a current report regarding a regulatory event and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Regulatory Status
- CFIUS Review Status: The U.S. Committee on Foreign Investment in the United States (CFIUS) completed a new 45-day review period on December 28, 2023.
- Investigation Phase: As CFIUS has not concluded its action, the proceeding has transitioned to a second 45-day investigation phase.
- Timeline: CFIUS advised counsel that the investigation will be completed no later than February 12, 2024.
- Transaction Condition: Obtaining CFIUS clearance is not a condition to closing the Transaction.
Outlook, Risks, and Management Commentary
Management Commentary: The Company and uBrigene previously submitted a voluntary notice to CFIUS. Following an initial review and investigation, CFIUS requested a withdrawal and re-filing on November 13, 2023, to allow more time for discussion regarding national security risks. The new review period commenced on November 14, 2023.
Risks and Contingencies: The primary contingency is the outcome of the ongoing CFIUS investigation into the national security risk posed by the sale of the Worcester facility to a Chinese contract development and manufacturing organization. While clearance is not required to close, the investigation remains pending.
Key Facts for Investor Verification
- Verify the final outcome of the CFIUS investigation expected by February 12, 2024.
- Confirm whether the sale of the Worcester facility proceeds despite the ongoing investigation, given that clearance is not a closing condition.
- Monitor for any additional disclosures regarding the nature of the national security risks identified by CFIUS.
- Check subsequent filings for the impact of this transaction on the Company's operational capacity and future revenue streams.